ClinicalTrials.gg
RecruitingNCT04525989PRORECTUpdated Aug 10, 2026

Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)

An interventional study of Radiation therapy in Rectal Cancer, sponsored by Alexander Valdman. Recruiting at 9 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Alexander Valdman · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.

Planned enrollment
20th of 40
254 · median 233
Started
2021
with 2 others
No phase
20 of 64
10 open now
Primary completion
2028-03
later than 16 of 21 live
Registered
46th of 64
by date
Lead sponsor
2 of 64
Alexander Valdman

Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 20th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2021, is one of 20 with no phase, reaches primary completion later than 16 of the 21 other live ones, and was the 46th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Rectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

To investigate a potential toxicity benefit of preoperative radiation therapy with protons compared to conventional photon beam radiation therapy in patients with locally advanced rectal cancer.

Read the detailed description

The aim of this study is to investigate whether proton beam radiotherapy in locally advanced rectal cancer can offer meaningful reductions in acute gastrointestinal toxicity compared to standard treatment with photons which may improve patient's tolerability of neoadjuvant chemotherapy.

There are currently no published clinical reports evaluating the use of proton therapy in the upfront treatment of locally advanced rectal cancer. There are further no published randomized trials comparing radiotherapy with photon vs proton in locally advanced rectal cancer.

This is a prospective randomized trial, initially run at the limited number of centres but later expanded to other centres participating in the Skandion network. Patients will be treated with short course 5 x 5 Gy radiation scheme with either photons (standard arm) or protons (Skandion clinic) followed by four to six cycles of combination chemotherapy (capecitabine and oxaliplatin) and surgery. The rectal tumour will be removed by TME/PME surgery or more extensive surgery if required because of tumour extent.

All patients will receive at least 4 courses of CAPOX (Capecitabine b.i.d.1000 mg/m2 day 1-14 every 3 weeks, Oxaliplatin 130 mg/m2 day 1 every 3 weeks) week 3-14, followed by surgery at week 17-20.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Proton therapy
  • Preoperative radiation
  • Short-course
  • Primary adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria - Primary tumour characteristics

  • -proven, newly diagnosed primary rectal adenocarcinoma, i.e. with the lowest part of the tumour less than 16 cm from the anal verge detected using a rigid rectoscope.
  • Locally advanced tumour fulfilling at least one of the following criteria on pelvic MRI indicating high risk of failing locally and/or systemically:

    • Clinical stage (c) T4b, i.e. infiltration of an adjacent organ or structure like the prostate, urinary bladder, uterus, sacrum, pelvic floor or side-wall (according to TNM version 8).
    • cT4a, i.e. peritoneal involvement.
    • Extramural vascular invasion (EMVI+).
    • N2-status regarded as according to ESGAR consensus criteria
    • Positive MRF, i.e. tumor or lymph node one mm or less from the mesorectal fascia.
    • Metastatic lateral nodes (lat LN+) according to ESGAR consensus criteria

Inclusion Criteria - General

  • Staging done within 6 weeks before start of radiotherapy. No to chemotherapy with CAPOX including adequate blood counts, (within 5 weeks prior to randomisation):

    • white blood count ≥4.0 x 10*9/L
    • count ≥100 x 10*9/L
    • clinically acceptable levels
    • creatinine levels indicating renal clearance of ≥50 ml/min
    • ˂35 µmol/l.
  • performance score ≤1
  • Patient is considered to be mentally and physically fit for chemotherapy with CAPOX as judged by the oncologist.
  • Age ≥18 years
  • Written .
  • Adequate potential for follow-up.

Exclusion Criteria:

  • Extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is seen.
  • Presence of metastatic disease or recurrent rectal tumour. Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn's disease or active ulcerative Colitis.
  • Concomitant , except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-free for at least 5 years.
  • Known DPD deficiency.
  • Any contraindications to MRI (e.g. patients with pacemakers).
  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
  • Concurrent uncontrolled medical conditions.
  • Any treatment for rectal cancer within the past month.
  • Pregnancy or breast feeding.
  • Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract.
  • (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation, even if controlled with medication) or myocardial infarction within the past 12 months.
  • Patients with symptoms of peripheral neuropathy.
  • Patients with pacemaker or ICD
  • Patients with bilateral hip protheses
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
254 participants (estimated)

Study arms

  • Experimental
    Proton therapy

    5 x 5 Gy External radiation therapy with Protons

    Radiation: Radiation therapy

  • Active comparator
    Photon therapy

    5 x 5 Gy External radiation therapy with Photons

    Radiation: Radiation therapy

Interventions

  • RadiationRadiation therapy

    5 x 5 Gy external radiation therapy

06

What researchers measure

Primary outcomes

  1. Incidence of acute grade 2-5 gastrointestinal toxicity

    The incidence of acute preoperative grade 2-5 gastrointestinal toxicity according to CTCAE v5.0 associated with proton vs. photon radiotherapy

    Time frame: From start of radiotherapy to planned start of the third (3) CAPOX cycle (week 9-10 of the trial)

Secondary outcomes

  1. Incidence of grade >2 hematologic and non-hematologic toxicity

    The incidence of grade \>2 hematologic (blood count, febrile neutropenia) and non-hematologic toxicity (general, genitourinary, gastrointestinal, skin) associated with protocol treatment, assessed by CTCAE v5.0 in the preoperative period, the postoperative period, and overall. Patient reported side-effects will be assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire, the QLQ-C30, version 3. The QLQ-C30 will be supplemented with the disease specific module (rectal-cancer) QLQ-CR29. During radiotherapy, daily reported symptoms will be investigated by a newly developed symptom scale, Radiotherapy related symptom assessment scale (RSAS). The questionnaire includes 13 items specific for current diagnose. The RSAS is a validated instrument for assessing symptom intensity and distress in patients with different cancer disease undergoing radiotherapy, with psychometric properties within the expected range.

    Time frame: Baseline up to five years after treatment

  2. Differences in patient reported outcomes (PRO)

    Differences in patient reported outcomes (PRO) between treatment arms in the preoperative period, the postoperative period, and overall

    Time frame: Baseline, Day 1-5, 2 and 3 weeks, 3, 6, 9, 12, 24, 36 and 60 months

  3. Proportion of patients being able to undergo full dose neoadjuvant chemotherapy

    Differences between treatment arms in proportion of patients being able to undergo full dose neoadjuvant chemotherapy i.e. at least 4 cycles of CAPOX or 6 cycles of FOLFOX

    Time frame: From week 3 until week 20 of the trial

  4. Tumour regression grading (mrTRG)

    Radiological assessment and comparison of tumour regression grading (mrTRG) between treatment arms

    Time frame: Baseline to response evaluation week 16-17 of the trial

  5. Cost effectiveness analysis measured by QALY

    Health economic comparison between proton and photon treatment. Cost effectiveness analysis measured by QALY

    Time frame: Time from randomization up to 5 years

Other outcomes

  1. Disease free survival

    Disease free survival after proton vs. photon treatment

    Time frame: Time from randomization until first recurrence, local/regional/systemic or death

  2. Overall survival

    Overall survival after proton vs. photon treatment

    Time frame: Time from randomization until death

  3. Quality of Life (QLQ-C30)

    Quality of life after proton vs. photon treatment (QLQ-C30)

    Time frame: Baseline, 3 weeks, 3, 6, 9, 12, 24, 36 and 60 months

  4. Difference in postoperative complications

    Difference in postoperative complications between study arms measured by LARS score

    Time frame: From week 17-20 of the trial up to 5 years

  5. Clinical complete remission (cCR)

    Proportion of patients who reach a clinical complete remission (cCR), enter a watch-and-wait period and remain free of regrowth at least one year

    Time frame: From start of treatment up to 1 year

  6. Incidence of acute lumbar plexus neuralgia

    Difference between treatment arms in acute lumbar plexus neuralgia grade 1-3 measured as a change from baseline according to CTCAE 5.0

    Time frame: From baseline until week 4 of the trial

  7. Exploratory: Concentrations of CD8+ and FOXP3 + tumour-infiltrating T cells

    Difference between treatment arms in concentrations of CD8+ and FOXP3 + tumour-infiltrating T cells after given radiotherapy

    Time frame: Postoperative pathology from week 17 until week 24 of the trial

  8. Exploratory: Difference in concentrations of CEA (carcinoembryonic antigen) between treatment arms

    Change from baseline in concentrations of circulating CEA (carcinoembryonic antigen) between treatment arms

    Time frame: CEA measurements at baseline, week 3, 6, 9 and 12 of the trial

07

Study locations

9 of 9 sites recruiting
08

References and documents

Publications

  • Pedone C, Sorcini B, Staff C, Farlin J, Fokstuen T, Frodin JE, Nilsson PJ, Martling A, Valdman A. Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): Initial dosimetric experience. Clin Transl Radiat Oncol. 2022 Dec 17;39:100562. doi: 10.1016/j.ctro.2022.100562. eCollection 2023 Mar. PubMed 36582423 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Mar 2028, 83 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 83 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 25, 2020
StartActual
Apr 20, 2021
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04525989
Lead sponsor
Alexander Valdman
Responsible party
Alexander Valdman (MD, PhD, Senior Consultant Radiation Oncologist, Karolinska University Hospital) — Sponsor-investigator
First posted
Aug 25, 2020
Start date
Apr 20, 2021
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Alexander Valdman, MD, PhD
Contact
alexander.valdman@regionstockholm.se
+46(0)700021317
Alexander Valdman, MD, PhD
principal investigator · Department of Radiotherapy, Karolinska University Hospital, Stockholm, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion